IDO1 and cancer: Additionally, two trials studied inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme that catalyzes the oxidation of L-tryptophan achieving metabolic modulation in multiple immune pathways in the cancer microenvironment.